Skip to main content
    B

    Beam Therapeutics Inc (BEAM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $20.94
    -1.89 (-8.28%)

    Market Cap: $2.36B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Beam Therapeutics Inc (BEAM) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Beam Therapeutics are Legend Biotech (LEGN), Structure Therapeutics Inc. American Depositary Shares (GPCR) and Vir Biotechnology (VIR). By market cap, Beam Therapeutics ranks 7th of the 13 companies on this page; Viridian Therapeutics (VRDN) is the largest at $3.51B.

    Peer Comparison

    BEAM's ROIC of -29.7% is above the peer median of -42.3%, and its revenue growth of -96.8% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Beam Therapeutics (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Legend Biotech Corp (LEGN)$3.39B266.5x2.3x-0.0%N/A32.0%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    Dyne Therapeutics Inc (DYN)$3.22BN/AN/A0.0%-42.9%0.0%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    Viridian Therapeutics Inc (VRDN)$3.51BN/A128.5x0.0%-41.8%-63.5%0.00%
    Biohaven Ltd. (BHVN)$2.09BN/AN/A0.0%-315.9%0.0%0.00%
    Tyra Biosciences Inc (TYRA)$1.38BN/AN/A0.0%N/A0.0%0.00%
    Sarepta Therapeutics Inc (SRPT)$1.72BN/A0.8x-5.9%-3.2%-4.5%0.00%
    Telix Pharmaceuticals Limited (TLX)$3.14BN/A5.3x3.8%-0.7%22.3%0.00%
    MBX Biosciences, Inc. Common Stock (MBX)$2.78BN/AN/A0.0%N/A0.0%0.00%
    Denali Therapeutics Inc (DNLI)$3.00BN/A159.3x0.0%N/A-100.0%0.00%
    Peer median$2.43B266.5x5.4x0.0%-42.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Beam Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Legend Biotech Corp (LEGN)
    Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology...
    LEGN competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors
    Dyne Therapeutics Inc (DYN)
    Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases...
    DYN competitors
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors
    Viridian Therapeutics Inc (VRDN)
    Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses.
    VRDN competitors
    Biohaven Ltd. (BHVN)
    Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders...
    BHVN competitors
    Tyra Biosciences Inc (TYRA)
    Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes...
    TYRA competitors
    Sarepta Therapeutics Inc (SRPT)
    Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy...
    SRPT competitors
    Telix Pharmaceuticals Limited (TLX)
    Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic...
    MBX Biosciences, Inc. Common Stock (MBX)
    MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment...
    MBX competitors
    Denali Therapeutics Inc (DNLI)
    Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.
    DNLI competitors

    Frequently Asked Questions About BEAM

    Who are Beam Therapeutics' main competitors?

    The companies most similar to Beam Therapeutics include Legend Biotech (LEGN), Structure Therapeutics Inc. American Depositary Shares (GPCR), Vir Biotechnology (VIR), Dyne Therapeutics (DYN) and Vera Therapeutics (VERA), listed from the closest match.

    Who is Beam Therapeutics' biggest competitor?

    Viridian Therapeutics (VRDN) is the largest of the similar companies at $3.51B; Legend Biotech (LEGN) is the closest match by business profile, size, sector and industry.

    How does BEAM stock compare with its competitors?

    BEAM's P/S is 15.0x against a peer median of 5.4x; its net margin is -73.9% against a peer median of 0.0%.

    Which of Beam Therapeutics' competitors pays a higher dividend?

    Beam Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Beam Therapeutics bigger than its competitors?

    No. Beam Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Viridian Therapeutics (VRDN) at $3.51B.